PMID- 22332735
OWN - NLM
STAT- MEDLINE
DCOM- 20121030
LR  - 20220317
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 110
IP  - 6 Pt B
DP  - 2012 Sep
TI  - Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
PG  - E228-34
LID - 10.1111/j.1464-410X.2011.10905.x [doi]
AB  - What's known on the subject? and What does the study add? Targeted agents with a 
      similar or different target molecule are often used sequentially in the treatment 
      of metastatic RCC. Two tyrosine kinase inhibitors, sorafenib and sunitinib, have 
      been reported to show little cross-resistance, when used sequentially. In 
      addition, a recent report showed that sunitinib rechallenge could potentially 
      benefit selected patients. This case series shows that patients once refractory 
      to sorafenib could regain disease control on rechallenge with sorafenib during 
      sequential treatment. Outcomes of the sorafenib rechallenge were not 
      significantly affected by the response to the initial sorafenib treatment or by 
      the duration of intervening treatments between first sorafenib and rechallenge. 
      OBJECTIVE: To investigate clinical outcomes of sorafenib rechallenge during 
      sequential therapy for patients with metastatic renal cell carcinoma (RCC). 
      PATIENTS AND METHODS: Patients with metastatic RCC who received sorafenib 
      rechallenge after failed treatment first with sorafenib and subsequently with 
      other agents, were retrospectively reviewed for patient characteristics, best 
      response, progression-free survival (PFS), and adverse events (AEs). RESULTS: Of 
      the 14 patients who received sorafenib rechallenge, 12 were evaluable for 
      response. Eleven patients had previously undergone nephrectomy, and 10 had 
      previously received systemic therapy, mostly interferon-alpha (nine patients) and 
      interleukin-2 (six patients), with a median duration of 9 months. The best 
      responses after the first sorafenib therapy were partial response (PR) in two 
      patients, stable disease (SD) in seven, and progressive disease (PD) in two. The 
      median PFS was 5.7 months. Initial sorafenib therapy was discontinued because of 
      PD in eight patients and AEs in four patients. Rechallenge with sorafenib was 
      undertaken after a 7.6 month median interval from the initial sorafenib 
      challenge. Eight patients achieved SD on sorafenib rechallenge and median PFS was 
      5.4 (95% confidence interval, 3.8-7.0) months. The outcome of the sorafenib 
      rechallenge was not significantly affected by the response to the initial 
      sorafenib treatment or by the duration of treatments received between first 
      sorafenib and rechallenge. No severe AE was newly observed on the rechallenge. 
      CONCLUSION: In the systemic treatment of advanced RCC, it was suggested that 
      patients once refractory to sorafenib could regain disease control on rechallenge 
      with sorafenib during sequential treatment.
CI  - (c) 2012 THE AUTHORS. BJU INTERNATIONAL (c) 2012 BJU INTERNATIONAL.
FAU - Nozawa, Masahiro
AU  - Nozawa M
AD  - Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, 
      Japan. nozawa06@med.kindai.ac.jp
FAU - Yamamoto, Yutaka
AU  - Yamamoto Y
FAU - Minami, Takafumi
AU  - Minami T
FAU - Shimizu, Nobutaka
AU  - Shimizu N
FAU - Hatanaka, Yuji
AU  - Hatanaka Y
FAU - Tsuji, Hidenori
AU  - Tsuji H
FAU - Uemura, Hirotsugu
AU  - Uemura H
LA  - eng
PT  - Journal Article
DEP - 20120214
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
CIN - BJU Int. 2012 Sep;110(6 Pt B):E235. PMID: 22332769
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Benzenesulfonates/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/*secondary
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/*pathology
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Pyridines/*therapeutic use
MH  - Retreatment
MH  - Retrospective Studies
MH  - Sorafenib
EDAT- 2012/02/16 06:00
MHDA- 2012/10/31 06:00
CRDT- 2012/02/16 06:00
PHST- 2012/02/16 06:00 [entrez]
PHST- 2012/02/16 06:00 [pubmed]
PHST- 2012/10/31 06:00 [medline]
AID - 10.1111/j.1464-410X.2011.10905.x [doi]
PST - ppublish
SO  - BJU Int. 2012 Sep;110(6 Pt B):E228-34. doi: 10.1111/j.1464-410X.2011.10905.x. 
      Epub 2012 Feb 14.